The worst Ebola virus disease outbreak in history ended in 2016 after infecting 28,600 people and killing about 11,300 worldwide.
The outbreak led to urgent action by medical experts across the world to combat this devastating disease; including the setting up of trials of vaccines to stop the disease taking hold.
This global commitment to develop a vaccine against the disease suggested eight options, out of a starting pool of 15 candidates, should be evaluated in clinical trials worldwide by the end of 2015.
Professor Sanjeev Krishna, of St George’s University of London’s Institute for Infection and Immunity, said: “An unprecedented Ebola outbreak showed how it is possible for academics, non-governmental organisations, industry and funders to work effectively together very quickly in times of medical crisis. The results of the trial show how a vaccine could best be used to tackle this terrible disease effectively.
“We need a system of specialists, medical experts and organisers that maintains vigilance against outbreak diseases like Ebola.
“We should continue to improve ways to make, evaluate and deliver vaccines when they are needed, often in parts of the world lacking in infrastructure for diagnosing infections and providing treatments.”
He explained that considering the persistent replication of the vaccine which is called rVSV-?GP-ZEBOV in children and adolescents, further studies investigating lower doses in this population are warranted.
The vaccine contains a non-infectious portion of a gene from the Zaire Ebola virus. The St George’s researchers worked with colleagues on a vaccine trial in Gabon.
In addition, lower vaccine doses should be considered when boosting individuals with pre-existing antibodies to Ebolavirus glycoprotein, a finding that has emerged after the vaccine was tested in a country that has experienced Ebolavirus outbreaks in the past.
The vaccine was one of two being examined as a ‘candidate’ option by the World Health Organisation to identify urgently a vaccine to combat the Ebola virus outbreak in West Africa.
The clinical trial was led by colleagues at University of Tübingen in Germany, coordinated by Professor Peter Kremsner with their partner institute CERMEL in Lambaréné, Gabon.
The Latest on: Ebola vaccine
- Novavax receives highest funding to develop COVID-19 vaccineon July 11, 2020 at 1:32 am
Vaccine developer Novavax was awarded over $1.6 billion by Operation Warp Speed to produce a vaccine against COVID-19.
- DRC's Success in Containing Ebola Serves as Lesson to Countries Battling COVID-19 - Democratic Republic of the Congo - ReliefWebon July 10, 2020 at 4:01 pm
English News and Press Release on Democratic Republic of the Congo about Health and Epidemic; published on 09 Jul 2020 by IPI ...
- African Union aims to scale up COVID-19 vaccine clinical trialson July 10, 2020 at 4:00 am
A new consortium aims to help increase the number of COVID-19 vaccine clinical trials conducted in Africa, to ensure that any successful vaccines that come to market will work for African populations.
- Want to volunteer for a COVID-19 vaccine trial? Here’s howon July 9, 2020 at 7:50 pm
On Wednesday, a website launched by the National Institute of Allergy and Infectious Diseases may make it easier to find volunteers.
- Johnson & Johnson Announces European Commission Approval for Janssen's Preventive Ebola Vaccineon July 7, 2020 at 10:40 am
NEW BRUNSWICK, N.J., Jul. 07 /CSRwire/ - On July 1, Johnson & Johnson announced that the European Commission (EC) has granted Marketing Authorisation for its Janssen Pharmaceutical Companies’ Ebola ...
- Novavax, Regeneron Get $2 Billion US Funds To Ramp Up Production Of Possible Coronavirus Vaccine, Treatmenton July 7, 2020 at 8:58 am
The contracts were announced Tuesday by the Department of Health and Human Services in a bid to get COVID-19 under control.
- Johnson & Johnson Gets European Approval for Ebola Vaccineon July 3, 2020 at 7:27 am
Johnson & Johnson JNJ ("J&J") announced that the European Commission (EC) has granted marketing approval to its two-dose Ebola vaccine regimen for the prevention of Ebola Virus caused by Zaire strain.
- Ebola vaccine approved for use by the European Commissionon July 2, 2020 at 7:07 am
The European Commission has granted Marketing Authorisation to Janssen for a new Ebola vaccine, developed in partnership with the University of Oxford.
- Johnson & Johnson Ebola vaccine OK'd in Europeon July 1, 2020 at 12:47 pm
As expected, the European Commission has approved Johnson & Johnson (JNJ +0.3%) unit Janssen Pharmaceutical Companies' two-dose Ebola vaccine regimen, Zabdeno (Ad26.ZEBOV) and Mvabea (MVA-BN-Filo ...
- BRIEF-Bavarian Nordic Announces European Marketing Authorization For Ebola Vaccineon July 1, 2020 at 6:49 am
BAVARIAN NORDIC ANNOUNCES EUROPEAN MARKETING AUTHORIZATION FOR EBOLA VACCINE * EUROPEAN COMMISSION HAS GRANTED MARKETING AUTHORIZATIO ...
via Google News and Bing News